Literature DB >> 10987115

Hepatitis E.

K Krawczynski1, R Aggarwal, S Kamili.   

Abstract

Hepatitis E, previously known as enterically transmitted non-A, non-B hepatitis, is an infectious viral disease with clinical and morphologic features of acute hepatitis. Its causative agent, hepatitis E virus, consists of small, 32- to 34-nm diameter, icosahedral, nonenveloped particles with a single-stranded, positive-sense, 7.5-kb RNA. The virus has two main geographically distinct strains, Asian and Mexican; recently, novel isolates from nonendemic areas and a genetically related swine HEV have been described. HEV is responsible for large epidemics of acute hepatitis and a proportion of sporadic hepatitis cases in the Indian subcontinent, southeast and central Asia, the Middle East, parts of Africa, and Mexico. The virus is excreted in feces and is transmitted predominantly by fecal-oral route, usually through contaminated water. Person-to-person transmission is uncommon. Clinical attack rates are the highest among young adults. Recent evidence suggests that humans with subclinical HEV infection and animals may represent reservoirs of HEV; however, further data are needed. Diagnosis of hepatitis E is usually made by detection of specific IgM antibody, which disappears rapidly over a few months; IgG anti-HEV persists for at least a few years. Clinical illness is similar to other forms of acute viral hepatitis except in pregnant women, in whom illness is particularly severe with a high mortality rate. Subclinical and unapparent infections may occur; however, chronic infection is unknown. No specific treatment is yet available. Use of clean drinking water and proper sanitation is currently the most effective method of prevention. Passive immunization has not been proved to be effective, and recombinant vaccines for travelers to disease-endemic areas and for pregnant women currently are being developed.

Entities:  

Mesh:

Year:  2000        PMID: 10987115     DOI: 10.1016/s0891-5520(05)70126-4

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  22 in total

1.  Assessment of HAV and HEV seroprevalence in children living in post-earthquake camps from Düzce, Turkey.

Authors:  Irfan Sencan; Idris Sahin; Demet Kaya; Sukru Oksuz; Mustafa Yildirim
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

2.  Characterization of hepatitis E virus recombinant ORF2 proteins expressed by vaccinia viruses.

Authors:  Nereida Jiménez de Oya; Estela Escribano-Romero; Ana-Belén Blázquez; María Lorenzo; Miguel A Martín-Acebes; Rafael Blasco; Juan-Carlos Saiz
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

3.  Guess who's coming to dinner? Emerging foodborne zoonoses.

Authors:  David N Fisman; Kevin Laupland
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

4.  Antiviral Candidates for Treating Hepatitis E Virus Infection.

Authors:  Natalie E Netzler; Daniel Enosi Tuipulotu; Subhash G Vasudevan; Jason M Mackenzie; Peter A White
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 5.  Zoonotic hepatitis E: animal reservoirs and emerging risks.

Authors:  Nicole Pavio; Xiang-Jin Meng; Christophe Renou
Journal:  Vet Res       Date:  2010-04-02       Impact factor: 3.683

6.  Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.

Authors:  David W Ouyang; David E Shapiro; Ming Lu; Susan B Brogly; Audrey L French; Robert M Leighty; Bruce Thompson; Ruth E Tuomala; Ronald C Hershow
Journal:  AIDS       Date:  2009-11-27       Impact factor: 4.177

7.  A Study of Hepatitis E in Pregnancy: Maternal and Fetal Outcome.

Authors:  Gowri Sayi Prasad; Sayi Prasad; Ashok Bhupali; Ajit N Patil; Kanishtha Parashar
Journal:  J Obstet Gynaecol India       Date:  2015-08-22

Review 8.  Molecular biology and pathogenesis of hepatitis E virus.

Authors:  Vivek Chandra; Shikha Taneja; Manjula Kalia; Shahid Jameel
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

9.  Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection.

Authors:  Manjula Kalia; Vivek Chandra; Sheikh Abdul Rahman; Deepak Sehgal; Shahid Jameel
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

10.  Hepatitis E epidemic, Uganda.

Authors:  Eyasu H Teshale; Christopher M Howard; Scott P Grytdal; Thomas R Handzel; Vaughn Barry; Saleem Kamili; Jan Drobeniuc; Samuel Okware; Robert Downing; Jordan W Tappero; Barnabas Bakamutumaho; Chong Gee Teo; John W Ward; Scott D Holmberg; Dale J Hu
Journal:  Emerg Infect Dis       Date:  2010-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.